Researchers at UCI Health have begun the world's first clinical trial for Huntington’s disease using neural stem cells. The phase 1b/2a trial aims to evaluate the safety and potential benefits of this innovative therapy, which could slow disease progression and reduce long-term care costs.
The US is not prepared for a mass disaster with multiple burn casualties, experts say. Gaps in everyday burn care for children must be addressed before it will be considered ready.
A clinical trial at UCI Health has tested a new CAR T-cell therapy for lupus patients. The treatment showed significant reversal of symptoms in the first trial participant, offering hope for future treatments.
Researchers at UC Irvine have developed a novel immunotherapeutic approach that targets cancer-associated glycans to trigger tumor cell death. The therapy, called GlyTR, has shown safety and effectiveness in models of various cancers, including leukemia, and is expected to pave the way for targeted T-cell therapy to solid tumors.